# Merck Sharp & Dohme LLC: Phase 3 study started recruiting, 646 planned (Ovarian Cancer, Peritoneal Cancer)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) |
| NCT ID | NCT07743164 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer |
| Intervention types | biological, drug |
| Target enrollment | 646 |
| Site countries | United States, Israel, Taiwan |
| Posted | 2026-08-03 |
| Planned start | 2026-10-07 |
| Event | Started recruiting |
| Event date | 2026-10-07 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 646 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07743164). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.